I
mprovements in cancer therapies have led to an increasing number of patients living many years after successful treatment. With overall 5-year survival rates in pediatric oncology exceeding 80% (1), the number of adult survivors of childhood or adolescent cancer, which is currently estimated to be 388 500 in the United States, is projected to surpass 500 000 by 2020 (2, 3) . This success is tempered by recognition of adverse late effects of cancer therapy and elevated mortality rates years after treatment. An 8-fold increased risk for death has been reported among 5-year survivors of childhood cancer compared with the age-and sex-matched general population (4) . Historically, the leading cause of death has been cancer recurrence. However, late effects of therapy have become the leading cause of death 30 years after diagnosis, and deaths are frequently attributed to premature cardiovascular disease (5) .
Because of the rarity of childhood cancer and the challenges of following patients across the life spectrum, most studies have relied on self-reported outcomes (6) , registry (7) , or death certificate data (8) to estimate the prevalence and incidence of adverse outcomes. Few studies have directly assessed survivors or done detailed clinical evaluations (9, 10) . This study aimed to report clinically evaluated cardiac outcomes among adults previously exposed to cardiotoxic therapies during treatment of childhood cancer.
METHODS

Participants
Participants for this analysis completed a baseline evaluation in the St. Jude Lifetime Cohort Study (SJLIFE), an ongoing study designed to facilitate longitudinal evaluation of health outcomes among adults who previously received treatment for childhood cancer. The study design and details have been previously published (11). To be enrolled in the cohort, participants must have been diagnosed with childhood cancer and treated at St. Jude Children's Research Hospital (Memphis, Tennessee), be 18 years or older, and have survived 10 years or more after diagnosis. This cross-sectional analysis includes data collected during the baseline evaluation. Participants (recruited from 44 states and 28 countries) must have been treated with cardiotoxic therapy (anthracycline chemotherapy or cardiac-directed radiation therapy) and completed the initial comprehensive risk-based health evaluation at St. Jude Children's Research Hospital as of 30 April 2013.
Survivors completed a detailed health questionnaire and had a medical evaluation according to the Children's Oncology Group's Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers (12) . Assessments included a history and physical examination, fasting laboratory testing (blood counts, metabolic panels, insulin levels, glycosylated hemoglobin levels, and lipid panels), echocardiography, and electrocardiography (ECG). We used VIVID 7 (GE Healthcare) (n = 1834) or iE33 (Philips Healthcare) (n = 19) machines for 2-dimensional Doppler ultrasonography echocardiography with harmonic imaging per American Society of Echocardiography guidelines and 3-dimensional imaging for left ventricular volumes (13) . All images were centrally reviewed by the echocardiography laboratory in the Department of Cardiovascular Medicine at the Cleveland Clinic (Cleveland, Ohio). A total of 1586 participants (86%) had evaluable echocardiograms sufficient for adequate determination of ejection fraction, and 1742 (94%) had echocardiograms sufficient for evaluation of cardiac valves. Twelve-lead ECGs (MAC 1200 Resting ECG System [GE Healthcare]) were obtained and centrally reviewed and coded per the Minnesota Code by the Epidemiological Cardiology Research Center at Wake Forest School of Medicine (Winston-Salem, North Carolina) (1798 participants had ECG).
We abstracted medical records to capture cumulative anthracycline exposure in mg/m 2 , mean cardiac radiation dose, and medical events during and after therapy. We converted anthracycline doses to doxorubicin isotoxic equivalents by summing doxorubicin, daunorubicin (×0.83), epirubicin (×0.67), idarubicin (×5), and mitoxantrone (×4) doses (14) . We estimated mean radiation doses in centigrays (cGy) to the heart using previously established methods by the radiation physicists at MD Anderson Cancer Center (Houston, Texas) (15) . Radiation treatment details included energy source, tumor dose, and field locations. Scatter dose to the heart was estimated for each case, regardless of radiation site and target volume. The SJLIFE protocol and study documents were approved by the institutional review board, and participants provided informed consent.
Outcomes
Outcomes included cardiomyopathy, coronary artery disease (CAD), valve function, and conduction or rhythm defects. Medical records were obtained to validate established cardiac outcomes reported before the SJLIFE assessment. Cardiomyopathy was defined as systolic ejection fraction less than 0.50 on echocardiography. Coronary artery disease was defined as a history of myocardial infarction, evidence of wall motion defect on echocardiography, or ischemia on ECG. Valves were assessed for function (regurgitation or stenosis) and structure (thickening or calcification) on echocardiography. Only functional valve findings (graded as mild, moderate, or severe) were used in the analysis (16, 17) . Conduction or rhythm disorders included major conduction abnormalities or arrhythmias (Appendix Table  1 , available at www.annals.org) as assessed by the Minnesota Code (18) .
Covariates
We assessed physical activity by asking survivors whether they participated in "usual weekly vigorous activities for at least 10 minutes at a time, such as: running, aerobics, wheelchair basketball, heavy yard work, or anything else that caused large increases in breathing or heart rate; or moderate activities for at least 10 minutes, such as: brisk walking, bicycling, gardening, manual operation of a wheelchair, or anything else that caused small increases in breathing or heart rate" (www.cdc.gov/nchs/data/nhanes/nhanes_09_10/paq_f .pdf). The frequency of exercise sessions per week was multiplied by the duration of each session and weighted by the standardized classification of the energy expenditure in metabolic equivalents (inactivity was defined as ≤450 metabolic equivalent minutes per week). Physical fitness was assessed by the 6-minute walk test (6MWT) (19) and considered abnormal if the participant walked fewer than 490 meters (20) . Risky drinking was defined as alcohol consumption of 5 drinks or more on 1 occasion or 15 drinks or more per week for men and consumption of 4 drinks or more on 1 occasion or 8 drinks or more per week for women (www.cdc.gov/alcohol/faqs.htm#heavyDrinking). Survivors who reported smoking within the past month were classified as current smokers, and those who smoked at least 100 cigarettes in their lifetime but not within the past month were considered former smokers. Dyslipidemia was defined as receiving treatment for a lipid abnormality or having a low-density lipoprotein cholesterol level of 4.14 mmol/L or greater (≥160 mg/dL), high-density lipoprotein cholesterol level less than 1.04
EDITORS' NOTES Context
Information on the presence of cardiac abnormalities among adult survivors of childhood cancer is limited.
Contribution
This prospective study identified evidence of cardiomyopathies, conduction or rhythm abnormalities, and coronary artery and valvular diseases in substantial numbers of adult survivors of childhood cancer who were exposed to cardiotoxic therapies, many of whom were asymptomatic.
Implication
Prospective studies to assess the potential value of screening for cardiac abnormalities in adult survivors of childhood cancer are needed.
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Cardiac Outcomes in Survivors of Childhood Cancer After Cardiotoxic Therapy mmol/L (<40 mg/dL) in men or less than 1.30 mmol/L (<50 mg/dL) in women, or triglyceride level greater than 1.70 mmol/L (>150 mg/dL). Diabetes was defined as receiving an oral hypoglycemic agent or insulin for diabetes or having a fasting blood glucose level of 6.99 mmol/L or greater (≥126 mg/dL) or glycosylated hemoglobin level of 6.5% or greater. Duplicate blood pressure readings were obtained in a seated position with both feet on the floor after a 5-minute rest, and the lowest reading was used for analysis. Hypertension was defined as receiving an antihypertensive agent or having a systolic blood pressure of 140 mm Hg or greater or diastolic blood pressure of 90 mm Hg or greater.
Statistical Analysis
Descriptive statistics were calculated for demographic, treatment, and cardiovascular risk factors (that is, body mass index at SJLIFE assessment, smoking, drinking, physical activity, hypertension, diabetes, and dyslipidemia). Chi-square tests were used to compare demographic and treatment characteristics between study participants and nonparticipants. Frequencies of cardiac conditions reported before or diagnosed during the on-campus evaluations were ascertained, and prevalence by age at detection was reported. Multivariable logistic models were used to evaluate associations between potential risk factors and cardiac conditions detected during the on-campus evaluations, excluding participants with cardiac outcomes detected before SJLIFE participation. Results are reported as odds ratios with 95% CIs. Covariates were selected because of their known and previously reported associations with cardiac outcomes in the general population and among adult survivors of childhood cancer. Proportions of participants with poor physical fitness (6MWT result ≤490 meters) were calculated and associations with cardiac conditions evaluated by multivariable logistic regression with age, sex, and height as covariates. We used multiple imputation (proc MI and proc MIANALYZE in SAS, version 9.3 [SAS Institute]) to account for any missing cardiac outcomes, radiation doses (n = 26), and 6MWT results (not due to a musculoskeletal cause) (n = 30). Markov-chain Monte Carlo methods were used for partial imputation of nonmonotone missing records (21) . We imputed monotone missing data using logistic regression. Pooled estimates of 20 multiply imputed data sets of the multivariable analyses for each outcome are reported as odds ratios with CIs. SAS, version 9.3, was used for all analyses. All statistical inference was based on 2-sided tests.
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RESULTS
Among 3054 participants exposed to cardiotoxic therapies, 1853 (61%) returned to St. Jude Children's Research Hospital for a risk-based medical evaluation. The Appendix Figure ( available at www.annals.org) shows reasons for nonparticipation. Participating survivors were more likely than nonparticipants to be women, be white, and have a history of leukemia. In addition, on average, participants were 8 months older at study entry and received less (9 mg/m 2 ) total anthracycline exposure ( Table 1) . Just more than one half of participants (52.3%) were men with a median age of 8 years (range, 0 to 24 years) at diagnosis and 31 years (range, 18 to 60 years) at the time of study. Median time from diagnosis was 22.6 years (range, 10 to 48 years), and nearly two thirds of survivors were exposed more than 20 years earlier. Most survivors received treatment for leukemia or lymphoma (67.2%). Other diagnostic categories included sarcoma (14.0%), Wilms tumor (7.2%), neuroblastoma (4.5%), central nervous system tumors (4.3%), and other tumors (2.8%).
Cardiotoxic exposures included anthracycline and radiation therapy. More than 82% were exposed to anthracycline, and 20.8% received cumulative doses in excess of 250 mg/m 2 . Fewer than one half of survivors received radiation to the heart, but 22.2% had a cardiac dose greater than 1500 cGy (Appendix Table 2 , available at www.annals.org). Cardiovascular risk factors present at the time of SJLIFE assessment included being overweight or obese (61.3%), smoking (23.7% current and 11.7% past), physical inactivity (49.6%), hypertension (23.3%), diabetes (6.8%), and dyslipidemia (61.9%). Table 2 shows the prevalence of each outcome and the result of cardiovascular screening. Cardiomyopathy was identified in 7.4% of the population, and 4.5% was detected during the SJLIFE assessment. Similarly, 3.8% and 4.4% of the population had evidence of CAD and a conduction or rhythm disorder, respectively (2.2% and 1.4% were newly identified by screening). Functional valve findings were frequent (28.0%), and most were identified during the SJLIFE assessment (23.8%). Table 3 shows the prevalence and severity of regurgitation and stenosis in each valve, most of which were mild cases of regurgitation of the tricuspid or pulmonary valves. Moderate and severe mitral regurgitation were identified in 26 (1.4%) survivors, and mitral stenosis was identified in 2 (0.1%) survivors. Sixty-four survivors (3.7%) had aortic regurgitation (16 moderate and 3 severe), and 31 (1.8%) had aortic stenosis (4 moderate and 9 severe). Mitral valve thickening was identified in 351 survivors (20.2%), annular calcifications in 177 (10.2%), aortic valve thickening in 414 (23.8%), and aortic calcifications in 107 (6.1%). One hundred sixty survivors (9.2%) had involvement of more than 1 valve.
The prevalence of each outcome increased with older age at evaluation and ranged from 10% to 37% among those older than 40 years ( Table 4) . Nearly 5% of participants aged 30 years or younger had evidence of cardiomyopathy. However, most outcomes were identified in participants aged 30 years or older, with Cardiac Outcomes in Survivors of Childhood Cancer After Cardiotoxic Therapy ORIGINAL RESEARCH the exception of valvular regurgitation or stenosis, which was identified in more than one quarter of survivors aged 18 to 29 years. Table 5 shows the associations among sex, age at diagnosis, age at evaluation, treatment factors, and traditional cardiovascular risk factors for cardiomyopathy and valvular disease. The odds of cardiomyopathy were significantly associated with male sex, anthracycline doses of 250 mg/m 2 or greater, cardiac radiation exposure greater than 1500 cGy, and hypertension. Younger age at diagnosis and higher radiation doses were associated with increased odds of functional valve findings. Associations between radiation and valvular disease varied according to anthracycline exposure (interaction P < 0.001). The highest odds were among survivors with the highest doses of radiation exposure and any anthracycline exposure. A reduction in the odds ratio for valve disease was noted among obese survivors and those with dyslipidemia. There were not enough cases of CAD and conduction or rhythm abnormalities to support a fully adjusted multivariable model, yet these outcomes seemed more common with older age (≥40 years) and among survivors with cardiac radiation doses of 1500 cGy or greater (Appendix Table 3 , available at www.annals.org).
Although most findings were asymptomatic (4 survivors reported intermittent chest pain, and 1 reported palpitations) and were only identified on screening, physical performance was significantly impaired. Survivors with cardiomyopathy and CAD had approximately twice the odds of having an abnormal 6MWT result than those without these cardiac effects ( Table 6 ). 
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DISCUSSION
Cardiovascular disease and cancer, the leading causes of death among U.S. adults, have been the targets of therapeutic advances and survival gains over the past 5 decades. However, among adults who previously received treatment for childhood cancer, cardiovascular disease can present at an earlier age with substantial morbidity rates, and the type and frequency of screening that should be used in this group remain unclear (6) . By systematically screening the largest prospective cohort of adults who previously received treatment for childhood cancer, we identified subclinical cardiovascular disease among persons generally too young for typical cardiovascular risk stratification. Although most cardiovascular disease was asymptomatic, significant associations with limited physical performance were identified.
Studies of cardiotoxicity after cancer therapy have largely focused on cardiomyopathy, whereas only a few have included a broader range of outcomes, such as CAD, valvular disease, and conduction or rhythm abnormalities (6, (22) (23) (24) (25) (26) . Frequencies of these findings have varied widely because of differing screening methods, diagnostic groups studied, outcome definitions, and study methods. In a systematic review, Kremer and colleagues (27) reported subclinical cardiomyopathy that ranged from 0% to 57%. However, many studies focused on a particular diagnosis and various definitions of cardiomyopathy. Among studies that evaluated a cross-section of childhood cancer diagnoses and more closely defined cardiomyopathy, the prevalence was narrower (between 5% and 20%).
Systematic screening identified a substantial number of survivors with asymptomatic cardiomyopathy who were at high risk for symptomatic heart failure. We identified 7.5% of survivors at a median age of 31 years with evidence of decreased systolic function, an estimate expected in a much older population. In a randomly selected healthy population, Redfield and colleagues (28) found an ejection fraction of 50% or less in 3% of those aged 45 to 54 years and 4.8% and 7.1% among those aged 55 to 64 years and 65 to 74 years, respectively. The risk for heart failure among persons with untreated systolic dysfunction is significant (29) and has been reported to be as high as 9% per year, with a 3-year mortality rate of 16% (30) . In fact, according to the American College of Cardiology/American Heart Association classification system, these cancer survivors have already progressed from stage A (high risk for congestive heart failure) to stage B (asymptomatic) heart failure (31).
The prevalence of CAD, valve findings, and conduction or rhythm defects has been less frequently described and commonly only within smaller diseasefocused studies. Coronary artery disease, typically associated with cardiac-directed radiation, has mostly been studied among survivors of Hodgkin lymphoma or breast cancer (32, 33) . However, the Childhood Cancer Survivor Study (CCSS) reported myocardial infarction in 0.7% of 14 358 survivors of childhood cancer at a median age of 27 years (6). In the SJLIFE cohort, the prevalence of ischemic disease was higher (3.8%), probably due to the inclusion of subclinical findings but also potentially influenced by the slightly older age of the cohort and longer follow-up. Studies among survivors of Hodgkin lymphoma have suggested a high mortality rate for radiation-induced CAD and a higher risk for patients treated at ages younger than 21 years (34). Coronary artery disease in this population is often proximal in the coronary tree, which results in considerable postinfarction myocardial loss. In fact, using computed tomography angiography screening in a pi- Cardiac Outcomes in Survivors of Childhood Cancer After Cardiotoxic Therapy ORIGINAL RESEARCH lot study of survivors of Hodgkin lymphoma from the SJLIFE cohort, we found obstructive and nonobstructive CAD, with 67% of the lesions located in the proximal coronary circulation (35) . Valvular disease has been mostly studied among survivors of Hodgkin lymphoma because mediastinal radiation therapy is commonly used for treatment (36). Based on self-report, the prevalence of valve abnormalities in the CCSS cohort was 1.6% across various diagnostic groups and was associated with radiation and anthracycline exposure (≥250 mg/m 2 ) (6). The prevalence of valve findings was much higher as a result of systematic screening. In our initial report (26), we identified an abnormality in 29% of the SJLIFE cohort and 56.7% of those who had radiation to the heart. In a recent study, van der Pal and colleagues (37) identified mild, moderate, and severe valve abnormalities in 169 of 545 survivors (31%) of childhood cancer. In our analysis, 28% of survivors had a functional valve finding. Six survivors had a bicuspid aortic valve, and none of them had a known history of rheumatic fever. In a populationbased study, Nkomo and colleagues (38) estimated the prevalence of mild or greater left-sided valve disease in the general population to be 0.7% (range, 0.5% to 1.0%) among persons aged 18 to 44 years and 13.3% (range, 11.7% to 15.0%) among those aged 75 years or older. The risk ratio for death among participants with valve disease was 1.36 (95% CI, 1.15 to 1.62) compared with those without it. Although we found mostly rightsided lesions, 13.7% of survivors had a left-sided lesion (8.2% mitral and 5.5% aortic).
Like the CCSS, we also identified an association between valvular disease and anthracycline exposure. The reason for this association is unclear, but it could result from drug-induced cardiomyopathy with secondary annular dilatation, which leads to valvular incompetence or toxicity to the valvular endothelium. An inverse relationship was noted with body mass index; however, this relationship has also been described in the general population (39, 40) and may be due to reduced image quality in obese patients or hemodynamic changes related to body habitus. Follow-up and focused study of valvular disease in this population is warranted.
Conduction and rhythm abnormalities after cancer therapy can vary in clinical significance and be more difficult to characterize. Reports have frequently focused on particular diagnostic groups and been associated with radiation or anthracycline exposures (7, 32, 41) . Myocardial fibrosis can induce an arrhythmogenic focus or interrupt the normal electrical impulse. Electrocardiographic abnormalities were identified in 4.4% of our cohort and were significantly associated with radiation exposure. This prevalence is lower than in our previous report, which also included noncardiotoxic therapies (26) , suggesting that these disorders may occur more frequently than expected but may not be exclusively associated with particular cardiotoxic exposures. Our estimated prevalence of a conduction or rhythm disorder beyond age 40 years was 10.3%, which is higher than that reported in the CCSS (42). The CCSS did not have the benefit of validated ECG screening of all survivors; therefore, it could not report on subclinical abnormalities and may have underestimated the prevalence. It also reported only grade 3 to 5 abnormalities according to the Common Terminology Criteria for Adverse Events; therefore, the lower prevalence might suggest that severe rhythm and conduction defects wane with time after diagnosis. Dedicated investigation and classification of ECG findings in cancer survivors after cardiotoxic and noncardiotoxic therapies are needed.
Given the lack of randomized, controlled trials to test screening practices, the current guidelines for the care of survivors of childhood cancer were developed by incorporating the best available evidence and expert clinical consensus. Only a few studies have investigated the effectiveness of adherence to these screening guidelines. In a clinic-based study of 370 survivors of childhood cancer with a median age at evaluation of 23.9 years (range, 5.3 to 57.2 years), Landier and colleagues (43) classified screening practices, based on the prevalence of late effects seen in the literature, as high (≥10%), intermediate (1% to ≤10%), and negligible (<1%) yield. Cardiomyopathy screening was determined to be of intermediate yield (6%), whereas yield of cardiac conduction screening was low (0.08%). Ischemic disease and cardiac valves were not evaluated. Two recent analyses assessed cost-effectiveness of echocardiographic screening of survivors for cardiomyopathy. Both concluded that the current guideline suggestions of imaging every 1 to 5 years are costeffective, although these benefits might be retained even if imaging was done less frequently or with other methods, such as cardiac magnetic resonance imaging (44, 45) . Our study provides important additional clini- 
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Cardiac Outcomes in Survivors of Childhood Cancer After Cardiotoxic Therapy cal variables not available in these studies, which relied on self-reported cardiac outcomes. Future longitudinal studies, which can be done in the SJLIFE cohort, are needed to better clarify the progression of cardiomyopathy, effects of treatment, and implications for clinical practice guidelines related to cardiovascular health surveillance as this population ages. Furthermore, our study assessed additional cardiac outcomes, and to our knowledge, cost-effectiveness studies have not yet been done in that area. The proportion of survivors with newly identified cardiac disease in our study was higher for all outcomes than previously reported but lowest for conduction or rhythm disorders. Several limitations should be considered when interpreting our results. Because of the 61% participation rate, selection bias could influence our findings. However, significant differences between participants and the source population have not been identified (46) . An on-campus evaluation was required, which excluded survivors who may have been unable to travel due to commitments, illness, or death and potentially affected our estimates of disease. In addition, medical records were not routinely obtained for persons who did not report a cardiac event, which may have biased our estimates. Our population was not compared with a control population with no history of cancer; in addition, although survivors will be invited to return for repeated evaluation, longitudinal assessments are currently lacking. Only survivors with a history of cardiotoxic therapies were studied, which limited the ability to generalize these findings and may have resulted in missed cardiac disease in survivors with other exposure histo- ries. A total of 267 echocardiograms were missing (101 participants did not complete scheduled cardiac evaluations, and 166 were missing for technical reasons, such as suboptimal recording and poor electrical transmission). All reasons were reviewed and treated as missing completely at random. We identified considerable cardiovascular disease in this large cohort of adult survivors of childhood cancer. The prevalence is inconsistent with the chronological age of the population and suggests a substantial future health care burden. Clinically, these data may guide stratification of risk factors, screening practices, health counseling, and potential therapeutic measures aimed at changing the disease trajectory in this young adult population. 
